Callisto Stockholders Approve Merger With Synergy Pharmaceuticals
NEW YORK, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Callisto Pharmaceuticals, Inc. (OTCQB:CLSP) ("Callisto") today announced that it convened its special meeting of stockholders yesterday and it has received the necessary approvals from its stockholders to authorize Callisto's merger with and into Synergy Pharmaceuticals Inc. ("Synergy") pursuant to the previously announced Agreement and Plan of Merger, dated July 20, 2012, as amended on October 15, 2012. Callisto and Synergy expect to close the merger as soon as practicable.
About Callisto Pharmaceuticals Inc.
Callisto is a development stage biopharmaceutical company. All of Callisto's drug candidates, currently plecanatide and SP-333 to treat GI disorders and diseases, are being developed exclusively by Synergy.
CONTACT: Investor Contact:
Danielle Spangler
The Trout Group
[email protected]
(646) 378-2924
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-30898-Callisto-Stockholders-Approve-Merger-With-Synergy-Pharmaceuticals.pdf
<!-- 90 -->
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
